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Summary 
Unravelling the role of cytoskeleton regulators may be complicated by adaptations to 
experimental manipulations. In this issue of Developmental Cell, Cerikan et al. 
(2016) reveal how acute effects of DOCK6 RhoGEF depletion on RAC1 and CDC42 
activation are reversed over time by compensatory mechanisms that re-establish 
cellular homeostasis. 
  
Targeted genetic disruption has become an essential component of the molecular 
toolkit that enables researchers to characterize their genes of interest. However, the 
choice of approaches raises important questions: Is permanent disruption or 
transient depletion (for example, by RNA interference) more informative of the “true” 
function of a gene under study? Similarly, is transient depletion a valid approach to 
model genetic disruptions observed in human diseases or pathologies? In this issue 
of Developmental Cell, Cerikan et. al. (2016) identify a compensatory mechanism 
that explains why acute depletion of the DOCK6 guanine nucleotide exchange factor 
(GEF) rapidly leads to cytoskeleton collapse due to reduced RAC1 and CDC42 
activity, and yet sustained depletion or complete loss of DOCK6 do not. These 
observations clarify how mutation of both DOCK6 alleles in fibroblasts from Adams-
Oliver Syndrome (AOS) patients has relatively mild effects on cytoskeletal structures 
and cell morphology (Shaheen et al., 2011) compared to the profound alterations 
and mitotic defects induced by small interfering RNA (siRNA)-mediated DOCK6 
knockdown (Cerikan et al., 2016). This study also demonstrates that, by examining 
the differences in responses to acute versus permanent gene depletion, the 
molecular basis for adaptations that re-establish homeostasis can be identified. 
Rho GTPases are regulators of cytoskeleton organisation and cell 
morphology (Sadok and Marshall, 2014). Their function as molecular switches 
upstream of signaling pathways that regulate actin dynamics is dependent on cycling 
between active GTP-bound and inactive GDP-bound states. Switching between 
these active and inactive states is regulated by the actions of GEFs, which stimulate 
GDP release to allow GTP binding, and GTPase-activating proteins (GAPs), which 
catalyse GTP hydrolysis. Mutations of Rho GTPases, GEFs or GAPs may have 
significant consequences on cytoskeletal structures and cell morphology, and may 
contribute to human genetic pathologies or diseases. Adams-Oliver Syndrome 
(AOS) is a condition characterized by abnormal skin development and limb 
malformations (Lehman et al., 2016), with four associated autosomal dominant and 
two recessive gene mutations contributing to AOS etiology. Interestingly, dominant 
ARHGAP31 mutations lead to gain-of-function of RAC1/CDC42 GAP activity 
(Southgate et al., 2011), while recessive DOCK6 mutations result in loss-of-function 
of RAC1/CDC42 GEF activity (Shaheen et al., 2011). The presence of two 
mechanisms that reduce RAC1/CDC42 activity in AOS is a striking indication of their 
importance in skin and limb development. 
Cerikan et. al. sought to characterize the function of DOCK6 to further 
elucidate the role of RAC1 and CDC42 regulation in AOS (Cerikan et al. 2016). 
Acute DOCK6 depletion using RNAi induced cytoskeletal collapse in HeLa cells, 
which could be rescued through expression of RNAi-resistant DOCK6, or 
constitutively-active RAC1. In addition, DOCK6 depleted cells had significant mitotic 
defects that could be reversed with active CDC42. Furthermore, RAC1 and CDC42 
activity were reduced and RHOA activity was increased in DOCK6 silenced cells, 
while inhibition of the RHOA effector ROCK kinases prevented cell rounding, 
indicating a role for RHOA activation in response to RAC1/CDC42 inhibition (Sander 
et al., 1999) in the morphological changes induced by DOCK6 depletion (Figure 1).  
Interestingly, the cytoskeletal defects following acute DOCK6 depletion were 
reversed 120 hours after RNAi treatment, despite continued DOCK6 protein 
reduction. To address the possibility that cells might overcome long-term DOCK6 
depletion, stable DOCK6 knockout (KO) cells were established using CRISPR/Cas9 
(Wright et al., 2016). DOCK6 KO cells, as well as fibroblasts from AOS patients, had 
shorter actin filaments and higher cytoplasmic G-actin, but did not undergo 
cytoskeletal collapse and were free of the mitotic defects observed in transiently 
DOCK6 depleted cells. DOCK6 KO cells also had CDC42, RAC1 or RHOA activity 
comparable to control cells, suggesting that long-term DOCK6 depletion, or mutation 
in AOS patients, may lead to adaptions in Rho GTPase activity. 
To identify factors that might re-equilibrate Rho GTPase activity, gene 
expression in fibroblasts from healthy controls or AOS patients were compared to 
DOCK6 KO and control cell lines. The small ubiquitin-like modifier ISG15 was 
reduced in AOS fibroblasts and DOCK6 KO cells relative to matched controls, and 
was also progressively reduced following DOCK6 RNAi treatment. Silencing ISG15 
expression in DOCK6 depleted cells prevented cytoskeleton alterations and 
normalized active RAC1, CDC42 and RhoA levels, while overexpressing ISG15 in 
DOCK6 depleted cells induced cytoskeleton defects, suggesting that ISG15 
downregulation compensates for reduced DOCK6.  
Given that DOCK6 depletion was associated with cytoskeleton alterations and 
increased G-actin levels, one possibility was that cytoplasmic G-actin sequestered 
the myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) 
transcription complex in the cytoplasm, blocking nuclear translocation and 
subsequent ISG15 gene transcription (Hermann et al., 2016). Consistent with this 
hypothesis, MRTF-A distribution was more cytoplasmic and synthetic promoter-
reporter assays revealed lower MRTF-A/SRF transcriptional activity in DOCK6 KO 
cells compared to control cells. 
To determine whether free or conjugated ISG15 mediated the suppression of 
DOCK6 depletion induced effects, the E2 ligase enzyme UbCH8 was knocked down 
along with DOCK6. Like ISG15 knockdown, UbCH8 depletion reversed cytoskeletal 
and morphological alterations. In agreement with previous studies (Zhao et al., 
2005), the scaffolding protein IQGAP1 (Watanabe et al., 2015) was confirmed as an 
ISGylated protein, which was reduced in DOCK6 KO cells. IQGAP1 depletion in 
DOCK6 KO cells caused cells to round up, while ectopic IQGAP1 expression 
reversed the cytoskeletal collapse induced by DOCK6 RNAi. These results are 
consistent with reduced ISG15 expression in DOCK6 KO cells promoting interactions 
between IQGAP1 and activated CDC42 and RAC1, resulting in stabilization of their 
active GTP-bound state. It is additionally possible that reduced ISG15 promotes the 
RAC1 and CDC42 effector function of IQGAP1 in regulating cytoskeleton 
organization (Watanabe et al., 2015). 
The ability of cells to adapt to environmental or genetic stressors by adjusting 
the outputs of complex cell signalling networks is an important attribute to maintain 
cell integrity and to promote survival. The approach described by Cerikan et. al. 
provides a platform for addressing adaptive mechanisms by comparing acute 
knockdown against stable deletion of a target gene. These findings also likely reflect 
the adaptive changes that naturally occur in cells harbouring potentially deleterious 
mutations. By implication, the use of acute depletion to model chronic loss-of-
function, or gene knockout to characterize acute functions, demands rigorous 
validation. 
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Figure 1. Acute vs sustained DOCK6 depletion/deletion. DOCK6 acts as a 
RAC1/CDC42 GEF under normal conditions. RNAi silencing of DOCK6 reduces 
RAC1/CDC42 activity, inducing cytoskeletal collapse and cell rounding. Cells adjust 
to continued DOCK6 loss by suppressing ISG15 expression, resulting in reduced 
ISGylation of IQGAP1 and restored CDC42/RAC1 activity. 
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